Wedbush ups SpringWorks target to $81, expects Merck KGaA ‘official’ offer soon
Wedbush raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $81 from $77 and keeps an Outperform rating on the shares ...
Morgan Stanley cuts Merck KGaA stock rating, target to EUR160
KGaA (MRK:GR) (OTC: MKGAF) stock from Overweight to Equalweight and reduced its price target from EUR190.00 to EUR160.00. The downgrade reflects a shift in the investment firm's perspective on the ...
SpringWorks Therapeutics CEO sells $2.56M in common stock
In a regulatory filing, SpringWorks Therapeutics (SWTX) disclosed that its CEO Saqim Islam sold 48K shares of common stock on February 10th in ...